Omalizumab for patients with severe and therapy-refractory atopic eczema?
Andres
Christian
C
Department of Dermatology and Allergy, Technical University Munich, Munich, Germany. christian.andres@lrz.tu-muenchen.de
Belloni
Benedetta
B
Mempel
Martin
M
Ring
Johannes
J
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000235:genetics; D000069444:Omalizumab; D012333:RNA, Messenger / Q000032:analysis
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D012333:RNA, Messenger; D000069444:Omalizumab; D007073:Immunoglobulin E